WO2024044709A3 - Anti-monomethyl auristatin antibodies and antibody fragments - Google Patents

Anti-monomethyl auristatin antibodies and antibody fragments Download PDF

Info

Publication number
WO2024044709A3
WO2024044709A3 PCT/US2023/072852 US2023072852W WO2024044709A3 WO 2024044709 A3 WO2024044709 A3 WO 2024044709A3 US 2023072852 W US2023072852 W US 2023072852W WO 2024044709 A3 WO2024044709 A3 WO 2024044709A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibody fragments
adc
monomethyl auristatin
payload
Prior art date
Application number
PCT/US2023/072852
Other languages
French (fr)
Other versions
WO2024044709A2 (en
Inventor
Joseph P. Balthasar
Brandon M. BORDEAU
Toan Duc NGUYEN
Joseph Ryan POLLI
Original Assignee
The Research Foundation For The State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation For The State University Of New York filed Critical The Research Foundation For The State University Of New York
Publication of WO2024044709A2 publication Critical patent/WO2024044709A2/en
Publication of WO2024044709A3 publication Critical patent/WO2024044709A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are compositions and methods for reducing off-target toxicity of antibody-drug conjugates (ADCs). The compositions comprise an ADC, and an agent targeted to the drug (payload) that is delivered by or derived from the ADC. The ADC and the agent targeted to the payload may be delivered together or separately in the treatment of various conditions (such as tumors) by ADCs. Examples of agents targeted to payload include antibodies, fragments, or modifications thereof.
PCT/US2023/072852 2022-08-24 2023-08-24 Anti-monomethyl auristatin antibodies and antibody fragments WO2024044709A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263373367P 2022-08-24 2022-08-24
US63/373,367 2022-08-24
US202363520689P 2023-08-21 2023-08-21
US63/520,689 2023-08-21

Publications (2)

Publication Number Publication Date
WO2024044709A2 WO2024044709A2 (en) 2024-02-29
WO2024044709A3 true WO2024044709A3 (en) 2024-04-04

Family

ID=90014109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072852 WO2024044709A2 (en) 2022-08-24 2023-08-24 Anti-monomethyl auristatin antibodies and antibody fragments

Country Status (1)

Country Link
WO (1) WO2024044709A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344583A1 (en) * 2012-12-07 2015-12-03 Amgen Inc. Bcma antigen binding proteins
WO2018177371A1 (en) * 2017-03-29 2018-10-04 Taipei Medical University Antigen-specific t cells and uses thereof
EP3725802A2 (en) * 2017-11-17 2020-10-21 ABL Bio Inc. Antibodies to alpha-synuclein and uses thereof
WO2021113740A1 (en) * 2019-12-04 2021-06-10 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates
US20220119441A1 (en) * 2019-03-08 2022-04-21 Levena Biopharma Co., Ltd. Method for preparing drug-linker mc-mmaf for antibody drug conjugate, and intermediates therein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344583A1 (en) * 2012-12-07 2015-12-03 Amgen Inc. Bcma antigen binding proteins
WO2018177371A1 (en) * 2017-03-29 2018-10-04 Taipei Medical University Antigen-specific t cells and uses thereof
EP3725802A2 (en) * 2017-11-17 2020-10-21 ABL Bio Inc. Antibodies to alpha-synuclein and uses thereof
US20220119441A1 (en) * 2019-03-08 2022-04-21 Levena Biopharma Co., Ltd. Method for preparing drug-linker mc-mmaf for antibody drug conjugate, and intermediates therein
WO2021113740A1 (en) * 2019-12-04 2021-06-10 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates

Also Published As

Publication number Publication date
WO2024044709A2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
WO2020126620A3 (en) Improved antibody-oligonucleotide conjugate
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
MX2021011242A (en) Extracellular vesicle conjugates and uses thereof.
MX2022001776A (en) Immuno oncology combination therapies with il-2 conjugates.
WO2019084064A3 (en) Compositions and methods for the depletion of cd117+ cells
WO2004032828A3 (en) Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
MX2020013832A (en) Binder-drug conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile.
MX2009003122A (en) Inhibitors of bruton's tyrosine kinase.
MX2011010673A (en) Nanoparticle formulations and uses therof.
MX2019013690A (en) Cyclodextrin protein drug conjugates.
EP4218826A3 (en) Antibody drug conjugates comprising sting agonists
MX2021010453A (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof.
MX2020012679A (en) Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof.
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2021012961A (en) Amatoxin antibody-drug conjugates and uses thereof.
MX2021009138A (en) Anti-cd228 antibodies and antibody-drug conjugates.
MX2023004032A (en) Immuno oncology therapies with il-2 conjugates.
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
WO2020118178A8 (en) Monomethyl fumarate-carrier conjugates and methods of their use
MX2023001143A (en) Anti-cd228 antibodies and antibody-drug conjugates.
MX2019008773A (en) Calicheamicin derivatives and antibody drug conjugates thereof.
WO2024044709A3 (en) Anti-monomethyl auristatin antibodies and antibody fragments
MX2022005249A (en) Anti-cd45 antibodies and conjugates thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23858316

Country of ref document: EP

Kind code of ref document: A2